Key result
Systemic thrombolytic therapy with Actilyse compared to Revelisa showed no statistically significant difference in the frequency of functional recovery on the MRS scale (P=0.905).
Why the study?
The proportion of ischemic stroke patients achieving functional independence after systemic thrombolytic therapy with different alteplase preparations was not established.
Cohort (n=195)
Open-label
p-value: p=0.905
OBJECTIVE: Was to determine the proportion of patients with ischemic stroke (IS) who achieved functional independence by the end of the hospitalization, among those who underwent systemic thrombolytic therapy (STT) with two different alteplase preparations (Actilyse and Revelisa). MATERIAL AND METHODS: An open, prospective observational non-interventional cohort study of the results of STT in patients with IS was carried out. The study included 195 patients, 123 men and 72 women aged 32 to 86 years, who received STT in the acute period of IS. Of these, 120 patients received Actilyse, 75 - Revelisa. RESULTS: =0.905), which showed that there was no statistical significance of the difference in the frequency of recovery of functional disorders on the MRS scale, in patients receiving STT with two different alteplase preparations. CONCLUSION: After STT with alteplase preparations, patients with IS experienced a significant improvement, which was expressed in a statistically significant decrease in the severity of neurological deficit and a decrease in the degree of disability. When comparing the results of STT with two different alteplase preparations, no statistically significant differences were found in terms of mortality, survival, and independence during the acute period of IS.
No takes yet. Share an insight, caveat, or question.
Belkina et al. (2021) conducted a cohort in Ischemic stroke (n=195). Alteplase (Actilyse) vs. Alteplase (Revelisa) was evaluated on Recovery of functional disorders on the MRS scale (functional independence by the end of hospitalization) (p=0.905). Systemic thrombolytic therapy with Actilyse compared to Revelisa showed no statistically significant difference in the frequency of functional recovery on the MRS scale (P=0.905).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: